IMS Health in $5.2bn leveraged buy-out

and mezzanine funds, will provide debt-financing on the deal and served as one of the buyers' advisers. BofA Merrill Lynch, Barclays Capital, Evercore Partners and JPMorgan Chase also counselled TPG and CPP. This is not the first time IMS has drawn...